| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/07/1997 | US5674893 Method for preventing reducing or risk of onset of cerebrovascular events employing an HMG CoA reductase inhibitor |
| 10/07/1997 | US5674888 Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| 10/07/1997 | US5674887 Prevention of bone resorption |
| 10/07/1997 | US5674882 Retroviral protease inhibiting compounds |
| 10/07/1997 | US5674860 Administering measured amounts of formoterol(or its salts or solvates) and budesonide by inhalation |
| 10/07/1997 | US5674858 Medicaments for treating gastrointestinal disorders |
| 10/07/1997 | US5674750 Continuous selective clonogenic expansion of relatively undifferentiated cells |
| 10/07/1997 | US5674681 Detecting association of a nonclassical major histocompatibility complex with a beta2 microglobin |
| 10/07/1997 | US5674527 Multicompartment container for intravenous injection comprising fat in water emulsions, sugar in first compartment, peptides and electrolytes in second compartment; shelf life, stability |
| 10/07/1997 | US5674472 Drug delivery |
| 10/07/1997 | US5674471 Aerosol formulations containing P134a and salbutamol |
| 10/02/1997 | WO1997035989A2 Cyclic nucleotide phosphodiesterase |
| 10/02/1997 | WO1997035976A2 Epidermal differentiation factor |
| 10/02/1997 | WO1997035962A1 Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
| 10/02/1997 | WO1997035870A1 Growth factor htter36 |
| 10/02/1997 | WO1997035856A1 Novel treatment for cns injuries |
| 10/02/1997 | WO1997035619A1 Opsonin-enhanced cells, and methods of modulating an immune response to an antigen |
| 10/02/1997 | WO1997035618A1 Dermatologic preparation |
| 10/02/1997 | WO1997035616A1 Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
| 10/02/1997 | WO1997035615A1 Compositions and methods for inhibiting clot formation |
| 10/02/1997 | WO1997035614A1 The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| 10/02/1997 | WO1997035611A1 Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof |
| 10/02/1997 | WO1997035602A1 Use of vasopressin receptor antagonist for regulation of acth release |
| 10/02/1997 | WO1997035601A1 TREATMENT OF CYSTIC DISEASE WITH TNF-$g(a) |
| 10/02/1997 | WO1997035587A1 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs |
| 10/02/1997 | WO1997035584A1 Method for treating pain |
| 10/02/1997 | WO1997035569A1 Use of heme oxygenase inhibitors to treat cancer |
| 10/02/1997 | WO1997035567A1 Pla2 inhibitors of angiogenesis |
| 10/02/1997 | WO1997035538A2 Tumor necrosis factor alpha convertase |
| 10/02/1997 | WO1997035480A1 Method of treating common cold or allergic rhinitis |
| 10/02/1997 | WO1997035479A1 Methods of treating venomous bites and stings |
| 10/02/1997 | WO1997028825A3 Spermatogenesis control |
| 10/02/1997 | WO1997026331A3 Use of neuronal apoptosis inhibitor protein (naip) |
| 10/02/1997 | WO1997019673A3 Reduction of hair growth |
| 10/02/1997 | DE19612463A1 Neues Protein mit differenzierungsinduzierender Aktivität für erythropoetische Zellen Novel protein differenzierungsinduzierender activity for erythropoietic cells |
| 10/02/1997 | CA2250459A1 Methods of treating venomous bites and stings |
| 10/02/1997 | CA2250403A1 Treatment of cystic disease with tnf-a |
| 10/02/1997 | CA2250042A1 Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain |
| 10/02/1997 | CA2249998A1 The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| 10/02/1997 | CA2249985A1 Tumour necrosis factor alpha convertase |
| 10/02/1997 | CA2249652A1 Method of treating common cold or allergic rhinitis |
| 10/02/1997 | CA2249354A1 Opsonin-enhanced cells, and methods of modulating an immune response to an antigen |
| 10/02/1997 | CA2249254A1 Epidermal differentiation factor |
| 10/02/1997 | CA2249208A1 Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof |
| 10/02/1997 | CA2248675A1 Cyclic nucleotide phosphodiesterase |
| 10/02/1997 | CA2248318A1 Growth factor htter36 |
| 10/01/1997 | EP0797997A2 Use of bradykinin antagonists for the preparation of medicaments |
| 10/01/1997 | EP0797995A2 Use of a 5-HT2 receptor antagonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis |
| 10/01/1997 | EP0797994A2 Use of one or more 5-HT2 receptor antagonists in the manufacture of a medicament for treating the symptoms of venomous bites and stings |
| 10/01/1997 | EP0797992A2 Use of taurine, homotaurine and/or methionine for inducing analgesia or anesthesia and treating or preventing ischaemic injury |
| 10/01/1997 | EP0797990A2 Use of steroid antagonists for the treatment and prophylaxis of dementia-related disorders |
| 10/01/1997 | EP0797988A2 Anti-angiogenic compositions and methods of use |
| 10/01/1997 | EP0797593A2 Improved cyclic crf antagonists |
| 10/01/1997 | EP0797451A2 Compositions containing hemicelluloses and polyphenols for treating gastrointestinal disorders |
| 10/01/1997 | EP0797442A1 Treatment of optic neuritis |
| 10/01/1997 | EP0797427A1 Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides |
| 09/30/1997 | US5672622 Phosphodiesterase inhibitor; rolipram |
| 09/30/1997 | US5672607 Antiviral naphthoquinone compounds, compositions and uses thereof |
| 09/30/1997 | US5672500 Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same |
| 09/30/1997 | US5672360 24-hour sustained release dosage of morphine or morphine sulfate |
| 09/30/1997 | US5672356 Bioadhesive pharmaceutical composition for the controlled release of active principles |
| 09/29/1997 | CA2200267A1 Novel sphingolipids and a process thereto |
| 09/27/1997 | CA2201089A1 Use of .alpha.1 -adrenoreceptor antagonists in the prevention and treatment of cancer |
| 09/27/1997 | CA2201088A1 Use of .alpha.1 -adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
| 09/27/1997 | CA2200040A1 Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders |
| 09/25/1997 | WO1997035019A1 Protein tyrosine phosphatases of hematopoietic cells |
| 09/25/1997 | WO1997035014A1 A KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF IλB$g(a) |
| 09/25/1997 | WO1997035012A1 Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| 09/25/1997 | WO1997035006A1 Human cell death-associated protein |
| 09/25/1997 | WO1997034927A1 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 09/25/1997 | WO1997034922A1 Treatment of preeclampsia, eclampsia or preterm labor with calcitonin gene related peptide and related drugs |
| 09/25/1997 | WO1997034911A1 Apoptosis inducing molecule ii |
| 09/25/1997 | WO1997034897A1 Fused imidazole derivatives as multidrug resistance modulators |
| 09/25/1997 | WO1997034871A1 Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| 09/25/1997 | WO1997034644A1 Topical formulations for the treatment of nail psoriasis |
| 09/25/1997 | WO1997034639A1 Animal model for transplantation |
| 09/25/1997 | WO1997034633A1 Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| 09/25/1997 | WO1997034624A1 Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| 09/25/1997 | WO1997034609A1 Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
| 09/25/1997 | WO1997034608A1 Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| 09/25/1997 | WO1997034599A2 Use of clotrimazole and related compounds in the treatment of diarrhea |
| 09/25/1997 | WO1997034597A1 Use of antiarrhythmic compounds for reducing post-infarction mortality |
| 09/25/1997 | WO1997034594A2 Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases |
| 09/25/1997 | WO1997034586A2 Device and method for treating ophthalmic diseases |
| 09/25/1997 | WO1997030704A3 Use of carbonic anhydrase inhibitors for treating macular edema |
| 09/25/1997 | WO1997026867A3 Solid instant-release forms of administration and process for producing the same |
| 09/25/1997 | WO1997021430A3 Surface-stabilised pharmaceutical preparation for application on the skin |
| 09/25/1997 | CA2250222A1 Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| 09/25/1997 | CA2249585A1 Animal model for transplantation |
| 09/25/1997 | CA2249551A1 A kinase capable of site-specific phosphorylation of i.kappa.b.alpha. |
| 09/25/1997 | CA2249481A1 Use of antiarrhythmic compounds for reducing post-infarction mortality |
| 09/25/1997 | CA2249196A1 Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| 09/25/1997 | CA2248977A1 Topical formulations for the treatment of nail psoriasis |
| 09/25/1997 | CA2248868A1 Apoptosis inducing molecule ii |
| 09/25/1997 | CA2248614A1 Human cell death-associated protein |
| 09/25/1997 | CA2242342A1 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 09/24/1997 | EP0796623A2 Pharmaceutical preparation for the treatment of blood coagulation disorders |
| 09/24/1997 | EP0796621A2 Preventing and treating periodontal disease |
| 09/24/1997 | EP0796618A1 Treatment and prophylaxis of pancreatitis |
| 09/24/1997 | EP0796617A1 Use of antiarhythmic compounds to reduce post-infarct mortality |